

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 30877

Title: A feasibility study of modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients

Reviewer's code: 02558978

Reviewer's country: Taiwan

Science editor: Jing Yu

Date sent for review: 2016-10-24 08:22

Date reviewed: 2016-11-14 20:03

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Manuscript ID: 30877 Manuscript title: A feasibility study of modified docetaxel, cisplatin and capecitabine (DCX) for stage IV gastric cancer in Japanese patients In the study, the authors designed the dose of docetaxel to 30 or 40 mg/m², which was a lower dose than that used in previous reports on DCX, and evaluated the safety and efficacy of our modified DCX (mDCX) regimen in Japanese patients. the manuscript presented that a modified docetaxel, cisplatin and capecitabine (DCX) treatment was safe and effective for stage IV gastric cancer. Three of the eight treated patients underwent conversion surgery and achieved long-term survival without recurrence. It is acceptable, although a small number of gastric cancer patients are included in this study.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 30877

Title: A feasibility study of modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients

Reviewer's code: 00503563

Reviewer's country: Japan

Science editor: Jing Yu

Date sent for review: 2016-10-24 08:22

Date reviewed: 2016-11-29 19:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors demonstrated the clinical effectiveness of modified docetaxel, cisplatin, and capecitabine (DCX) in Japanese patients with stage IV gastric cancer. There are some queries and comments. Comments 1. In Table 1, macroscopic type should be indicated. 2. In the present study, three patients underwent gastrectomy with lymphadenectomy. Did these patients received adjuvant chemotherapy? 3. Case 8 had para-aortic metastatic lymph nodes before chemotherapy using DCX. Were these para-aortic lymph nodes dissected? 4. How about pathological response in primary tumor sites of case 5 and 8?